Preview this article 1 min Regeneron's $2 billion plan for its Saratoga County facility got a big boost recently. © 2025 ...

Earlier in December, Regeneron Pharmaceuticals reported encouraging Phase 1/2 data for its investigational multiple myeloma ...

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

Merck's oral PCSK inhibitor for cholesterol, enlicitide, and its cancer antibody-drug conjugate sacituzumab tirumotecan ...

Regeneron Pharmaceuticals (REGN) shares have drifted lower over the past week even as the stock remains solidly higher over ...

It's full steam ahead for a new Regeneron facility in Saratoga Springs. The company has learned that Saratoga County's ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

In this video, Carolyn K. Pan, MD, a clinical professor of ophthalmology at Stanford University, discussed highlights in wet ...